Robert Shahverdyan, MD, from Hamburg, Germany presented one-year results from the VENOS-1 first-in-human study, which examined the VelocityTM Percutaneous Arteriovenous Fistula (pAVF) System during the recent Controversies in Dialysis Access (CiDA) meeting held in Washington, D.C.
Renal Interventions has published an overview of Dr. Shahverdyan’s presentation which included an overview of 1st generation pAVF systems and their limitations and data from the VENOS-1 study (NCT 05757726), a prospective, single-arm, early feasibility study of the Venova Medical’s Velocity pAVF System, an innovative medical technology being developed to use a minimally invasive technique to create an arterio-venous fistula (AVF) for hemodialysis vascular access.
CLICK HERE to view the article in Renal Interventions.